The flaws of total systems therapy with biological preparations in psoriasis


Cite item

Full Text

Abstract

Basic studies of the etiology and pathogenesis ofpsoriasis created prerequisites for development of a group of novel gene engineering biological preparations (GEBP). The experience accumulated by the present time in the use of biological therapy preparations demonstrates the flaws of GEBP (initial inefficiency, “escape effect”), suggests protocols of transition from one preparation to another, and demonstrates the safety of combined use of GEBP and systemic cytostatics. Clinical use of GEBP in refractory cases is discussed.

About the authors

E. V Sokolovskiy

St. Petersburg I.P. Pavlov State Medical University

Кафедра дерматовенерологии; доктор мед. наук, профессор 199034, St. Petersburg, Russia

Larisa S. Kruglova

Moscow Research and Practical Center of Dermato-Venereology and Cosmetology

Email: kruglovals@mail.ru
MD, PhD, DSc, prof. Moscow, Russia

E. S Ponich

Khanty-Mansi Clinical Dermato-Venereological Center

кандидат мед. наук 628912, Khanty-Mansiisk, Russia

References

  1. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N. Engl. J. Med. 2009; 361(12): 496-509.
  2. Sabat R., Philipp S., Höflich C., Kreutzer S., Wallace E., Asadullah K., et al. Immunopathogenesis of psoriasis. Exp. Dermatol. 2007; 16(10): 779-98.
  3. Piruzian E., Bruskin S., Ishkin A., Abdeev R., Moshkovskii S., Melnik S., et al. Integrated network analysis of transcriptomic and proteomic data in psoriasis. BMC Syst. Biol. 2010; 4: 41. doi: 10.1186/1752-0509-4-41.
  4. Duffin K.C., Chandran V., Gladman D.D., Krueger G.G., Elder J.T., Rahman P. Genetics of psoriasis and psoriatic arthritis: Update and future direction. J. Rheumatol. 2008; 35(7): 1449-53.
  5. Pastore S., Mascia F., Mariani V., Girolomoni G. The epidermal growth factor receptor system in skin repair and inflammation. J. Invest. Dermatol. 2008; 128(6): 1365-74.
  6. Bowcock A.M. Understanding the pathogenesis of psoriasis, psoriatic arthritis, and autoimmunity via a fusion of molecular genetics and immunology. Immunol. Res. 2005; 32(1-3): 45-56.
  7. Wagner E.F., Schonthaler H.B., Guinea-Viniegra J., Tschachler E. Psoriasis: what we have learned from mouse models. Nat. Rev. Rheumatol. 2010; 6(12): 704-14. doi: 10.1038/nrrheum.2010.157.
  8. Ghoreschi K., Weigert C., Röcken M. mmunopathogenesis and role of T cells in psoriasis. Clin. Dermatol. 2007; 25(6): 574-80.
  9. Nestle F.O. Psoriasis. Curr. Dir. Autoimmun. 2008; 10: 65-75. doi: 10.1159/000131424.
  10. Torti D.C., Feldman S.R. Interleukin-12, interleukin-23, and psoriasis: current prospects. J. Am. Acad. Dermatol. 2007; 57(6): 1059-68.
  11. van Beelen A.J., Teunissen M.B., Kapsenberg M.L., de Jong E.C. Interleukin-17 in inflammatory skin disorders. Curr. Opin. Allergy Clin. Immunol. 2007; 7(5): 374-81.
  12. Menter A., Gottlieb A., Feldman S.R., Van Voorhees A. S., Leonardi C.L., Gordon K.B., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section I. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J. Am. Acad. Dermatol. 2008; 58(5): 826-50. doi: 10.1016/j.jaad.2008.02.039.
  13. Tsai T.F., Ho V., Song M., Szapary P, Kato T, Wasfi Y, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br. J. Dermatol. 2012; 167(5): 1145-52.
  14. Leonardi C.L., Kimball A.B., Papp K.A., Yeilding N., Guzzo C., Wang Y., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008; 371(9625): 1665-74.
  15. Федеральные клинические рекомендации по ведению больных псориазом. М.; 2013. Available at: http://www.cnikvi.ru/docs/clinic_recs/bolezni-kozhi-i-pridatkov.../psoriaz.doc
  16. Efalizumab SPC (Эфализумаб SPC). Available at: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/raptiva/H-542-PI-en.pdf. Accessed 20 Nov 2014.
  17. Papp K.A., Tyring S., Lahfa M. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol. 2005; 152(6): 1304-12.
  18. Menter A., Tyring S., Gordon K. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J. Am. Acad. Dermatol. 2008; 58(1): 106-15.
  19. Papp K., Langley R., Lebwohl M., Krueger G.G., Szapary P., Yeilding N.; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008; 371(9625): 1675-84. doi: 10.1016/S0140-6736(08)60726-6.
  20. EMEA Press release, 19 Feb 2009. Available at: http:// PDFs/EPAR/raptiva/2085709en.pdf. Accessed 20 Nov 2014.
  21. Reich K., Burden A.D., Eaton J.N., Hawkins N.S. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br. J. Dermatol. 2012; 166(1): 179-88. doi: 10.1111/j.1365-2133.2011.10583.x.
  22. Mrowietz U., de Jong E.M., Kragballe K., Langley R., Nast A., Puig L., et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J. Eur. Acad. Dermatol. Venerol. 2013; 168(4): 825-36.
  23. Puig L., Dauden E., Carrascosa J.M. Commentary on European and British guidelines for the treatment of psoriasis. Actas Dermosifiliogr. 2010; 24(12): 1458-67.
  24. Reich K., Nestle F.O., Papp K., Ortonne J.P., Evans R., Guzzo C., et al.; EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005; 366(9494): 1367-74.
  25. NICE Technology appraisal, Psoriasis - ustekinumab (TA180). Ustekinumab for the treatment of adults with moderate to severe psoriasis. Available at: http://www.nice.org./ uk/nicemedia/pdf/TA180Guidance.pdf. Accessed on Jan 2010.
  26. Hsu L., Snodgrass B.T., Armstrong A.W. Antidrag antibodies in psoriasis: a systematic review. Br. J. Dermatol. 2014; 170(2): 261-73.
  27. Signorovitch J.E., Betts K.A., Yan Y.S., LeReun C., Sundaram M., Wu E.Q., Mulani P. Comparative efficacy of biologic treatments for moderate to severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response. Br. J. Dermatol. 2014; 172(2): 504-12.
  28. Kimball A.B., Papp K.A., Wasfi Y., Chan D., Bissonnette R., Sofen H., et al.; on behalf of the PHOENIX 1 investigators. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J. Eur. Acad. Dermatol. Venereol. 2013; 27(12): 1535-45.
  29. Strober B., Buonanno M., Clark J.D., Kawabata T., Tan H., Wolk R., et al. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br. J. Dermatol. 2013; 169(5): 992-9.

Copyright (c) 2015 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies